Earl M. Collier, Jr. manages and has built several of Genzymes newer businesses, including its cardiovascular, genetics and oncology business units. He also has been responsible for building the biosurgery business and for the companys efforts in multiple sclerosis and other immune disorders. He has also led some of Genzymes significant acquisitions and the formation of MG Biotherapeutics, Genzymes joint venture with Medtronic Inc., which is focused on cardiac cell therapy.
Mr. Collier joined Genzyme full time in 1997, but his relationship with the company dates to 1990, when he began working with Genzyme as an outside lawyer and strategic advisor.
Mr. Collier has more than 30 years of experience in healthcare. From 1991-1995, he was president of Vitas Healthcare Corp., the largest provider of hospice services in the United States. Between 1981 and 1991, Mr. Collier was a partner at Hogan & Hartson law firm in Washington, D.C. He served as deputy administrator for the Health Care Financing Administration (HCFA) in Baltimore, MD, during the Carter Administration.
From 1977 to 1979, Mr. Collier was deputy administrator of the New York State offices of Health Systems Management. He was an associate at Covington and Burlington law firm in Washington, D.C., from 1974 to 1977. Mr. Collier began his legal career in Washington as a clerk for the U.S. Court of Appeals for the District of Columbia Circuit.
Mr. Collier sits on the boards of deCODE genetics, Newton-Wellesley Hospital, and Pervasis Therapeutics. He earned a B.A. at Yale University and a J.D. at the University of Virginia Law School.
Executive Vice President
Genzyme Corporation
